| Earnings call
Lilly says more than half a million people have filled a prescription through the Medicare Bridge
Also on the Q3 2026 call: the EloraTZP phase 3 trials will use a slower dose escalation schedule. Details are in the call log below.
Eli Lilly obesity and diabetes tracker
Every Lilly weight-loss and diabetes medicine in one place: what is approved, what is in trials, what Lilly has said lately, and what is scheduled next. Each line links to the page or source behind it.
Last checked . Company statements are labeled as company-reported.
173Lilly-sponsored trials in the Atlas tracker
79of them phase 3
26recruiting now, plus 6 not yet recruiting
31more active but no longer recruiting
Trial counts come from the Atlas trial tracker (ClinicalTrials.gov records, data of October 29, 2026). They include trials where a Lilly medicine is the comparator, and a registry entry describes a study, not a result.
Latest from Lilly
| Trial results
Retatrutide beat Ozempic 2 mg in a type 2 diabetes trial
TRANSCEND-T2D-2: A1C fell more and weight loss was more than double, as Lilly reported it.
| Trial results
Retatrutide and sleep apnea
Two placebo-controlled phase 3 trials published in the New England Journal of Medicine.
| Trial results
Retatrutide TRIUMPH-1 in NEJM
About 24% to 25% average weight loss at the two higher doses over 80 weeks.
The Lilly pipeline, medicine by medicine
Status is what the Atlas has verified. Trial counts are from the tracker, with the number still active in brackets.
| Medicine | What it is | Where it stands | Trials (active) |
|---|---|---|---|
| Tirzepatide (Zepbound, Mounjaro) | Once-weekly GIP and GLP-1 injection | Approved. Lilly's Q3 release lists a new Mounjaro approval to reduce cardiovascular risk in adults with type 2 diabetes. | 69 (21) |
| Orforglipron (Foundayo) | Once-daily GLP-1 pill | FDA approved for weight loss on April 1, 2026. Lilly cited a prespecified ACHIEVE-4 analysis on the Q3 call. | 35 (15) |
| Retatrutide | Once-weekly GIP, GLP-1 and glucagon injection | Investigational, in phase 3. The Atlas reported Lilly's plan for a 2027 filing; no filing date was given on the Q3 call. | 25 (9) |
| Eloralintide | Once-weekly amylin injection | Investigational. Phase 3 is registered, and Lilly said the EloraTZP combination phase 3 trials will start "imminently" with a slower dose escalation. | 17 (14) |
| LY4086940 (GGG Tri-Agonist III) | Program Lilly lists as "GGG Tri-Agonist III"; Lilly has not published its structure | Phase 1 completed August 2026. Phase 2 is registered and not yet recruiting, with a listed start in November 2026. Lilly did not mention it on the Q3 call. | 2 (1) |
| Mazdutide | GLP-1 and glucagon injection | Investigational. Lilly-sponsored trials listed are phase 1 and 2. | 4 (1) |
| Macupatide, bimagrumab | Next-generation obesity candidates | Early trials only. The Atlas has no medicine page for either yet. | 3 each (3 and 1) |
Browse every trial, with filters, in the pipeline tracker. Not sure what an LY number means? See Lilly LY numbers explained. Compare medicines side by side in Compare.
What Lilly said on the Q3 2026 call
The call was held on October 29, 2026. Everything below is company-reported, paraphrased from a third-party transcript copy; Lilly's own transcript was not checked. None of it is independent data.
| Topic | What was said | Who |
|---|---|---|
| Medicare GLP-1 Bridge | More than half a million people have filled a prescription for a Lilly medicine through the program since July 1. About 75% of people entering the Bridge go on to an injectable, about 80% are new to incretin therapy, and 7 in 10 new patients start a Lilly obesity medicine. | Dave Ricks, Ilya Yuffa |
| Medicare, next step | Lilly wants the program moved into the Part D benefit, with carrier work for calendar year 2028, and is optimistic about permanent coverage. | Dave Ricks |
| EloraTZP phase 3 | The highest-dose combination arm in phase 2b had a higher rate of stopping because of adverse events. Phase 3 will use a slower, optimized dose escalation schedule and is expected to start imminently. Eloralintide alone had fewer adverse-event discontinuations than placebo. No amounts or dates were given. | Dan Skovronsky |
| Zepbound persistence | Among covered patients, staying on Zepbound is tracking close to the 16 to 18 months seen with Trulicity, and self-pay is described as close to the covered market. | Ilya Yuffa |
| Foundayo | Lilly cited a prespecified analysis from ACHIEVE-4 showing 16% lower risk of a four-part cardiovascular event versus insulin glargine. | Call summary |
| LY4086940, retatrutide filing | LY4086940 was not mentioned. No retatrutide filing date was given. | n/a |
Read the Lilly numbers in context: Medicare and GLP-1 medicines | Eloralintide | TRANSCEND-T2D-2.
Coming up
- November 2026: listed start of the LY4086940 phase 2 trial (NCT07890376), 460 people planned. Listed dates can move.
- Fourth quarter 2026: Lilly says the EloraTZP phase 3 trials begin. Registered as AMPLIFY-1 and AMPLIFY-2.
- December 7, 2026: Lilly Innovation Day, 9:00 AM to 1:00 PM EST, per Lilly's events page.
- With Q4 results: Lilly said it will share 2027 financial guidance then. The Atlas will note anything it says about medicines.
Where the official words are
The Atlas links the originals so you can check us. Lilly events and presentations | Lilly news releases | ClinicalTrials.gov.
Follow this page
New Lilly items appear in the Lilly-only feed (RSS) within a day. Prefer everything? Use the full Atlas news feed. An RSS reader such as Feedly or Inoreader will show new items without you checking the site. Following Novo Nordisk too? See the Novo Nordisk tracker.
Questions about Lilly's weight-loss medicines
Which Lilly weight-loss medicines are approved?
Tirzepatide (Zepbound for weight, Mounjaro for type 2 diabetes) and orforglipron (Foundayo), approved for weight loss on April 1, 2026. Retatrutide and eloralintide are investigational.
When could retatrutide be approved?
Lilly has said it plans a filing in 2027, as the Atlas reported. No approval date exists, and Lilly gave no filing date on its October 29 call.
What is EloraTZP?
A combination of eloralintide and tirzepatide. Phase 2b results in type 2 diabetes were announced on September 30, 2026, and phase 3 is expected to begin soon. See eloralintide.
Is this medical advice?
No. This page tracks company news and published trials. Ask a clinician about any medicine that might suit you.
Sources
- Eli Lilly and Company, third-quarter 2026 earnings call, October 29, 2026, third-party transcript copy. Company-reported statements.
- Eli Lilly and Company, third-quarter 2026 results release.
- NCT07890376, LY4086940 phase 2 registry record.
- Atlas trial tracker, built from ClinicalTrials.gov.
- Eli Lilly and Company, events and presentations (Innovation Day, December 7, 2026).